Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7455853 | 0.84 | GPR119 (0.59) | GPR119HRH3CHEK2ALDH1A1PDE4A | |
| SCHEMBL29862463 | 0.79 | GPR119 (0.54) | GPR119HRH3CHEK2 | |
| SCHEMBL2503394 | 0.79 | GPR119 (0.54) | GPR119HRH3CHEK2 | |
| SCHEMBL30701894 | 0.79 | GPR119 (0.54) | GPR119HRH3CHEK2 | |
| SCHEMBL567454 | 0.79 | MMP1 (0.44) | GPR119STSALDH1A1 | |
| SCHEMBL567453 | 0.79 | MMP1 (0.44) | GPR119STSALDH1A1 | |
| SCHEMBL23360301 | 0.78 | IKBKB (0.54) | GPR119HRH3CHEK2 | |
| SCHEMBL15586785 | 0.78 | GPR119 (0.53) | GPR119HRH3CHEK2ALDH1A1PDE4A | |
| SCHEMBL29862689 | 0.78 | IKBKB (0.54) | GPR119HRH3CHEK2 | |
| SCHEMBL13324476 | 0.77 | GPR119 (0.91) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612382-B2 | Process for preparing 6-substituted-1-(2H)-isoquinolinones and intermediate compound | VALO HEALTH INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20250296923-A1 | PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMEDIATE COMPOUND | VALO HEALTH, INC. (US) | 2025-09-25 | — | — | US | disclosed |
| CN-119630643-A | Process and intermediate compounds for the preparation of 6-substituted-1- (2H) -isoquinolinones | 瓦洛健康公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20240287031-A1 | PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMEDIATE COMPOUND | VALO HEALTH, INC. (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240287030-A1 | PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMEDIATE COMPOUND | VALO HEALTH, INC. (US) | 2024-08-29 | — | — | US | disclosed |
| EP-4402129-A1 | <SMALLCAPS/>? ? ?H? ? ? ? ?PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2)-ISOQUINOLINONES AND INTERMEDIATE COMPOUND | Valo Health, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| WO-2024030854-A1 | PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMEDIATE COMPOUND | VALO HEALTH, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| US-8722671-B2 | Isoquinoline derivatives | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-8722671-B2 | Isoquinoline derivatives | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-8501736-B2 | Isoquinoline derivatives | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| EP-1899322-B1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF RHO-KINASE | SANOFI AVENTIS (FR) | 2009-09-02 | — | — | EP | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20090088429-A1 | Isoquinoline Derivatives | SANOFI-AVENTIS (FR) | 2009-04-02 | — | — | US | disclosed |
| US-20090088429-A1 | Isoquinoline Derivatives | SANOFI-AVENTIS (FR) | 2009-04-02 | — | — | US | disclosed |
| EP-1910333-A1 | PIPERIDINYL-SUBSTITUTED ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | Sanofi-Aventis (FR) | 2008-04-16 | — | — | EP | disclosed |
| EP-1899322-A1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF RHO-KINASE | Sanofi-Aventis (FR) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007012421-A1 | PIPERIDINYL-SUBSTITUTED ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007012421-A1 | PIPERIDINYL-SUBSTITUTED ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007000240-A1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF RHO-KINASE | SANOFI-AVENTIS (DE) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | MYLK2, MYLK, RHOT2 | GPR119 1661/4885HRH3 3637/4885CHEK2 1893/4885 |
| US-20240287031-A1 | PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMEDIATE COMPOUND | ROCK1, ROCK2, CIT | GPR119 3900/4885HRH3 2915/4885CHEK2 1095/4885 |
| US-20250296923-A1 | PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMEDIATE COMPOUND | ROCK1, ROCK2, CIT | GPR119 3900/4885HRH3 2915/4885CHEK2 1095/4885 |
| US-12612382-B2 | Process for preparing 6-substituted-1-(2H)-isoquinolinones and intermediate compound | ROCK1, RHOA, ABL1 | GPR119 4002/4885HRH3 2299/4885CHEK2 881/4885 |
| US-20240287030-A1 | PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMEDIATE COMPOUND | ROCK1, ROCK2, CIT | GPR119 3900/4885HRH3 2915/4885CHEK2 1095/4885 |
| US-20090088429-A1 | Isoquinoline Derivatives | MYLK2, MYLK, RHOT2 | GPR119 2425/4885HRH3 3122/4885CHEK2 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.